Cell Signaling Technology (CST), a life science discovery technology company and leading provider of antibodies, kits, and services, has announced the launch of InTraSeq™ Single Cell Analysis Reagents, a reliable, efficient and convenient way to simultaneously detect and study intracellular proteins and the transcriptome in a single-cell experiment, while guaranteeing a robust RNA signal. By combining InTraSeq technology with the 10x Genomics Single Cell Gene Expression Assay, researchers can rapidly categorize sub-populations of cells and unbiasedly resolve signaling pathways with single-cell resolution.

“For 25 years, CST has been the ‘go-to’ antibody company for studying cellular signaling and PTMs. InTraSeq technology brings this unparalleled expertise to single-cell analysis,” said Roby Polakiewicz, Chief Scientific Officer at CST. "The result is a groundbreaking new way to study intracellular signaling pathways at the single-cell level, representing a completely novel dataset that has been missing in current single-cell experiments. This enables researchers to comprehensively dissect the molecular mechanisms behind disease development using everything from surface markers to intracellular proteins, and PTMs to transcription factors—and finally, RNA sequencing—all in one assay.”

Features and Benefits of InTraSeq Technology

• Simultaneous and reliable detection of RNA as well as extracellular, cytoplasmic, and intracellular proteins in thousands of cells at the single-cell level.
• Massively parallel, unbiased categorization of cell subpopulations and cell states using intracellular proteins, while guaranteeing a robust RNA signal.
• Convenient and efficient methodology that enables multiple stopping points and a straightforward, streamlined protocol with just one hour of hands-on time.
• Ability to deconvolute the molecular mechanisms of disease in one experiment with increased confidence in results.

“Signaling transduction and gene transcription events, along with their relationship during T cell activation and cytokine signaling, have been a long-standing interest in the field of immunology,” said Dr. Vijay Kuchroo, PhD, DVM, Samuel L. Wasserstrom Professor of Neurology at Harvard Medical School, Senior Scientist at Brigham and Women’s Hospital, and a paid consultant for CST. “By measuring the abundance of proteins, along with their PTMs and the transcriptome at the exact moment for each individual cell, we can gain important insights into how signaling cascades interact with transcriptional regulation.”

InTraSeq Single Cell Analysis Reagents are available now as a ready-to-use cocktail of primary antibodies to 29 intracellular protein targets and two surface proteins, and as individual antibodies to 31 intracellular proteins and six surface proteins. They are reactive to humans and mice and have been validated by CST for use on the 10x Genomics Chromium instruments. Antibody cocktails relevant to signaling pathways related to immunology, cancer, and additional research areas are in development.